Dr. Dandoy on TMA Risk After Pediatric Allogenic Stem Cell Transplant

TWiPO #83 - Dr. Christopher Dandoy on transplant-associated thrombotic microangiopathy (TA-TMA)Подробнее

The diagnosis and management of TA-TMA in pediatric patientsПодробнее

TA-TMA: an increasingly identified complication post-transplantПодробнее

Dr. Dandoy on Overcoming Challenges with TA-TMAПодробнее

Emerging treatment options for HSCT-TMAПодробнее

A Retrospective Look at the Management of HCST-TMAПодробнее

Post transplant complications: a focus on TMAПодробнее

Transplant Associated Thrombotic Microangiopathy (TA-TMA)Подробнее

Dr. Khaled on Recognition and Treatment of TA-TMAПодробнее

Narsoplimab for TA-TMAПодробнее

Survival Outcomes in HSCT-TMA After TransplantПодробнее

HCST-TMA Management: Narsoplimab Clinical TrialsПодробнее

The importance of precision dosing in transplant recipientsПодробнее

Drugs under investigation for the treatment of TA-TMAПодробнее

Pediatric BMT - Optimizing Outcomes After TransplantПодробнее

Renal and Hepatic Endothelial injury in BMT - Christopher Dandoy, MD, MSПодробнее

Long Term Effects of Pediatric Stem Cell TransplantationПодробнее

David Shyr, MD - Pediatric Stem Cell Transplantation - Stanford Medicine Children’s HealthПодробнее

Risk of teeth-related infections in allogeneic stem cell transplantationПодробнее